Market perspective Fast-track approval reflects urgency in tackling obesity Oral therapies may capture ~20% of the market by 2030 Expands access for patients preferring pills over injections While Novo Nordisk may offer slightly higher weight loss with its oral option, ease of use and flexibility position this therapy as a strong competitor
Providers should concentrate on three areas: With these programs and mostly limited adaptations of existing solutions, there is significant market potential for digital weight loss and behavior change-supporting solutions
Youre already using Semaglutide or Tirzepatide but are unsure how to balance nutrition and exercise
Your body composition will start shifting
Recently, GLP-1 was highlighted as a regulator of diverse pathways, but its potential as the therapeutic target of depressive disorder was not described comprehensively
Our findings suggest that tirzepatide, through its dual GIP/GLP-1 action, may be superior as a non-IOPlowering adjunct or even as a primary preventive agent in glaucoma management among patients with diabetes, the researchers wrote in their paper
